KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbCellera Biologics (ABCL) EBITDA (2020 - 2026)

AbCellera Biologics filings provide 7 years of EBITDA readings, the most recent being -$41.4 million for Q1 2026.

  • Quarterly EBITDA rose 14.28% to -$41.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$139.4 million through Mar 2026, up 19.46% year-over-year, with the annual reading at -$146.3 million for FY2025, 11.63% up from the prior year.
  • EBITDA hit -$41.4 million in Q1 2026 for AbCellera Biologics, down from -$10.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $169.1 million in Q1 2022 and bottomed at -$57.2 million in Q3 2025.
  • Average EBITDA over 5 years is -$20.2 million, with a median of -$37.2 million recorded in 2024.
  • Peak annual rise in EBITDA hit 210.67% in 2022, while the deepest fall reached 3991.23% in 2022.
  • AbCellera Biologics' EBITDA stood at -$30.6 million in 2022, then crashed by 55.1% to -$47.4 million in 2023, then rose by 21.21% to -$37.4 million in 2024, then skyrocketed by 71.94% to -$10.5 million in 2025, then plummeted by 294.52% to -$41.4 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's EBITDA are -$41.4 million (Q1 2026), -$10.5 million (Q4 2025), and -$57.2 million (Q3 2025).